The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial
Abstract
Background Antagonists of N-methyl-D-aspartate-type glutamate receptors (NMDAR) induce symptoms that closely resemble those of schizophrenia, including negative symptoms. D-serine is a naturally occurring NMDAR modulator that reverses the effects of NMDAR antagonists in animal models of schizophrenia. D-serine effects have been assessed previously for treatment of established schizophrenia, but not in the early stages of the disorder. We aimed to assess effects of D-serine on negative symptoms in at risk individuals.Methods We did a double-blind, placebo-controlled, parallel-group randomised clinical trial at four academic US centres. Individuals were eligible for inclusion in the study if they were at clinical high risk of schizophrenia, aged between 13-35 years, had a total score of more than 20 on the Scale of Prodromal Symptoms (SOPS), and had an interest in participation in the clinical trial. Exclusion criteria included a history of suprathreshold psychosis symptoms (ie, no longer qualifying as prodromal) or clinical judgment that the reported symptoms from the SOPS were accounted for better by another disorder (eg, depression). Randomisation was done using a generated list with block sizes of four. Participants were stratified by site, with participants, investigators, and assessors all masked through use of identical looking placebos and centralised drug dispensation to study assignment. D-serine (60 mg/kg) was given orally in divided daily doses for 16 weeks. The primary endpoint was for negative SOPS, measured weekly for the first 6 weeks, then every 2 weeks. Participants who received at least one post-baseline assessment were included in analysis. Serum cytokine concentrations were collected at baseline, midpoint, and endpoint to assess the mechanism of action. Safety outcomes including laboratory assessments were obtained for all individuals. This trial is registered with ClinicalTrials.gov, number NCT0082620.Findings We enrolled participants between April 2, 2009, and July 23, 2012. 44 participants were randomly assigned to receive either D-serine (n=20) or placebo (n=24); 35 had assessable data (15 D-serine, 20 placebo). D-serine induced a 35·7% (SD 17·8) improvement in negative symptoms, which was significant compared with placebo (mean final SOPS negative score 7·6 [SEM 1·4] for D-serine group vs 11·3 [1·2] for placebo group; d=0·68, p=0·03). Five participants who received D-serine and nine participants who received placebo discontinued the study early because of withdrawn consent or loss to follow-up (n=8), conversion to psychosis (n=2), laboratory-confirmed adverse events (n=2), or protocol deviations (n=2).Interpretation This study supports use of NMDAR-based interventions, such as D-serine, for treatment of prodromal symptoms of schizophrenia. On the basis of observed effect sizes, future studies with sample sizes of about 40 per treatment group would be needed for confirmation of beneficial effects on symptoms and NMDAR-related inflammatory changes. Long-term studies are needed to assess effects on psychosis conversion in individuals at clinical high risk of schizophrenia.Funding National Institutes of Health.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Published studies have revealed beneficial effects in schizophrenia patients as an add-on to maintenance medication [100][101][102][103] and ongoing studies are following up their results and including additional metrics of efficacy such as brain GSH imaging in order to reflect the BBB permeability analyses of NAC that have been performed in rodents 104 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [100]
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Estimating the Dimension of a Model
Schwarz, G. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344136 · Cited by 47,033
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
Simpson, G. M., B., M., B., G., Angus, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,265
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Self-citationInflammation and immunity in schizophrenia: implications for pathophysiology and treatment
Khandaker, G. M., Cousins, L., Deakin, J., Lennox, B. R., Yolken, R., & Jones, P. B. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)00122-9 · Cited by 926
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y., & Chong, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 676
Ruhrmann, S., Schultze-Lutter, F., Salokangas, R. K. R., Heinimaa, M., Linszen, D., Dingemans, P., Birchwood, M., Patterson, P., Juckel, G., Heinz, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.206 · Cited by 632
Cannon, T. D., Chung, Y., He, G., Sun, D., Jacobson, A., van Erp, T. G. M., McEwen, S., Addington, J., Bearden, C. E., Cadenhead, K., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.023 · Cited by 599
Self-citationD-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., LANGE, N. D., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 572
The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up
McGlashan, T. H., Walsh, B. C., & Woods, S. W. (2010) · Cited by 566
Self-citationBerk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., Judd, F., Katz, F., Katz, P., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.004 · Cited by 552
Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Self-citationCytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis
Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.03.005 · Cited by 501
Gonzalez-Burgos, G., & Lewis, D. A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs010 · Cited by 478
Long-term Follow-up of a Group at Ultra High Risk (“Prodromal”) for Psychosis
Nelson, B., Yuen, H. P., Wood, S. J., Lin, A. P., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M. B., Foley, D. L., Brewer, W. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.1270 · Cited by 434
NMDA Receptor and Schizophrenia: A Brief History
COYLE, J. T. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs076 · Cited by 432
Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Self-citationKantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 414
Self-citationHeresco‐Levy, U., Javitt, D. C., Ebstein, R. P., Vass, Á., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Self-citationSchobel, S., Lewandowski, N., Corcoran, C., Moore, H., Brown, T., Malaspina, D., & Small, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.115 · Cited by 384
Self-citationvan der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D. H., Yung, A. R., McGorry, P., & Cuijpers, P. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.004 · Cited by 384
Glutathione Precursor, N-Acetyl-Cysteine, Improves Mismatch Negativity in Schizophrenia Patients
Lavoie, S., Murray, M. M., Deppen, P., Knyazeva, M. G., Berk, M., Boulat, O., Bovet, P., Bush, A. I., Conus, P., Copolov, D., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301624 · Cited by 371
SAFTEE: a technique for the systematic assessment of side effects in clinical trials.
Levine, J., & Schooler, N. (1986) · PubMed · Cited by 330
Negative symptoms in individuals at clinical high risk of psychosis
Piskulic, D., Addington, J., Cadenhead, K., Cannon, T. D., Cornblatt, B., Heinssen, R., Perkins, D., Seidman, L., Tsuang, M., Walker, E. F., et al. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.018 · Cited by 298
Self-citationTsai, G. E., & Lin, P. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790361452 · Cited by 269
High dose D-serine in the treatment of schizophrenia
Kantrowitz, J. T., Malhotra, A. K., Cornblatt, B. A., Silipo, G. S., Balla, A., Suckow, R. F., D’Souza, C., Saksa, J. R., Woods, S. W., & Javitt, D. C. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.012 · Cited by 253
Self-citationMoghaddam, B., & Krystal, J. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs075 · Cited by 238
Perkins, D. O., Jeffries, C. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Seidman, L. J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu099 · Cited by 238
Self-citationEffect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
Umbricht, D., Alberati, D., Martin‐Facklam, M., Borroni, E., Youssef, E. A., Ostland, M., Wallace, T. L., Knoflach, F., Dorflinger, E. E., Wettstein, J. G., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.163 · Cited by 234
Addington, D. E., Addington, J., & Atkinson, M. J. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00070-4 · Cited by 225
Lin, C., Huang, C., Chang, Y., Chen, P., Lin, C.-Y., Tsai, G. E., & Lane, H. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.02.009 · Cited by 202
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Lane, H., Lin, C., Huang, Y.-J., Liao, C.-H., Chang, Y.-C., & Tsai, G. E. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990939 · Cited by 179
Kinon, B. J., Millen, B. A., Zhang, L., & McKinzie, D. L. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.03.016 · Cited by 169
Stojanovic, A., Martorell, L., Montalvo, I., Ortega, L., Monseny, R., Vilella, E., & Labad, J. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.12.005 · Cited by 169
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168
Self-citationBehrens, M. M., & B, T. J. S. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.06.002 · Cited by 163
Instrument for the Assessment of Prodromal Symptoms and States
McGlashan, T. H., Miller, T. J., Woods, S. W., Hoffman, R. E., & Davidson, L. (2001) · Springer eBooks · doi:10.1007/978-94-010-0892-1_7 · Cited by 159
Self-citationCorcoran, C. M., Kimhy, D., Parrilla-Escobar, M. A., Cressman, V. L., Stanford, A. D., Thompson, J. L., Ben‐David, S., Crumbley, A. H., Schobel, S., Moore, H. M., et al. (2010) · Psychological Medicine · doi:10.1017/s0033291710000802 · Cited by 156
Self-citationMeyer, E. C., Carrión, R. E., Cornblatt, B. A., Addington, J., Cadenhead, K. S., Cannon, T. D., McGlashan, T. H., Perkins, D. O., Tsuang, M. T., Walker, E. F., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt235 · Cited by 153
Self-citationBayesian Measures of Model Complexity and Fit
Spiegelhalter, D. J., Best, N. G., Carlin, B. P., & Van Der Linde, A. (2002) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00353 · Cited by 151
Hashimoto, K., Fujita, Y., Horio, M., Kunitachi, S., Iyo, M., Ferraris, D. V., & Tsukamoto, T. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.002 · Cited by 128
Valmaggia, L. R., Stahl, D., Yung, A. R., Nelson, B., Fusar-Poli, P., McGorry, P. D., & McGuire, P. K. (2013) · Psychological Medicine · doi:10.1017/s0033291713000251 · Cited by 121
IV glycine and oral d-cycloserine effects on plasma and CSF amino acids in healthy humans
D’Souza, D. C., Gil, R. B., Cassello, K., Morrissey, K., Abi‐Saab, D., White, J., Sturwold, R., Bennett, A., Karper, L. P., Zuzarte, E., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00133-x · Cited by 111
Weiser, M., Heresco‐Levy, U., Davidson, M., Javitt, D. C., Werbeloff, N., Gershon, A. A., Abramovitch, Y., Amital, D., Doron, A., Konas, S., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07031 · Cited by 106
Self-citationJavitt, D., Balla, A., Burch, S., Suckow, R., Xie, S., & Sershen, H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300313 · Cited by 98
Self-citationBugarski‐Kirola, D., Wang, A., Abi‐Saab, D., & Blaettler, T. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.03.007 · Cited by 97
Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.
Javitt, D. C. (2009) · PubMed · Cited by 94
Self-citationLeiderman, E. A., Zylberman, I., Zukin, S. R., Cooper, T. B., & Javitt, D. C. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00585-4 · Cited by 90
Self-citationEarly Intervention in Psychotic Disorders
Miller, T. J., Mednick, S. A., McGlashan, T. H., Libiger, J., & Johannessen, J. O. (2001) · Springer eBooks · doi:10.1007/978-94-010-0892-1 · Cited by 80
Adams, D. H., Zhang, L., Millen, B. A., Kinon, B. J., & Gómez, J. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/758212 · Cited by 74
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods, S. W., Walsh, B. C., Hawkins, K. A., Miller, T. J., Saksa, J. R., D’Souza, D. C., Pearlson, G. D., Javitt, D. C., McGlashan, T. H., & Krystal, J. H. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.09.008 · Cited by 61
Self-citationGozzi, A., Herdon, H. J., Schwarz, A. J., Bertani, S., Crestan, V., Turrini, G., & Bifone, A. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1271-z · Cited by 61
Clinical development of pomaglumetad methionil: A non-dopaminergic treatment for schizophrenia
Kinon, B. J., & Gómez, J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.002 · Cited by 48
Balla, A., Schneider, S., Sershen, H. W., & Javitt, D. C. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.006 · Cited by 16
Self-citationEarly Intervention in Psychotic Disorders
Carroll, A. (2002) · Psychiatric Services · doi:10.1176/appi.ps.53.3.352 · Cited by 16
Arango, C., Nasrallah, H. A., Lawrie, S. M., Lohmann, T. O., Zhu, J. L., Garibaldi, G. M., Wang, A., & Bugarski‐Kirola, D. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.038 · Cited by 11
Blaettler, T., Bugarski‐Kirola, D., Fleischhacker, W. W., Bressan, R. A., Arango, C., Abi‐Saab, D., Napieralski, J. A., Dixon, M., & Marder, S. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.07.036 · Cited by 11
Cited by
Sorted by citations
Barnes, T. R. E., Drake, R., Paton, C., Cooper, S. J., Deakin, J. F. W., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I. R., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 615
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature reviews. Neuroscience · doi:10.1038/nrn4002 · Cited by 377
Self-citationLinking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis
Hardingham, G. E., & Do, K. Q. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.19 · Cited by 304
The NMDA Receptor and Schizophrenia
Balu, D. T. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.01.006 · Cited by 303
Metadata
- Authors
- Kantrowitz, J. T., Woods, S. W., Petkova, E., Cornblatt, B., Corcoran, C. M., Chen, H., Silipo, G., & Javitt, D. C.
- Affiliations
- Nathan Kline Institute for Psychiatric Research (US)
- Yale University (US)
- Zucker Hillside Hospital (US)
- Columbia University (US)
- University of Florida (US)
- Corresponding author
- Javitt, Daniel C
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 2
- Issue
- 5
- Pages
- 403-412
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2070856797
- Cited by
- 148
- References
- 62
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 7 · 2022: 11 · 2021: 19 · 2020: 15 · 2019: 19 · 2018: 17 · 2017: 16 · 2016: 20 · 2015: 4
- FWCI
- 15.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1 TR000040)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- D-serine, negative symptoms, schizophrenia, clinical high risk, prodromal psychosis, NMDA receptor modulation, serum cytokines, mechanism of action, early intervention
- MeSH terms
- Adolescent, Adult, Double-Blind Method, Female, Humans, Male, Schizophrenia, Serine, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Risk Assessment, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
